- Home
- FMFC vs NTHI Comparison
FMFC vs NTHI Comparison
Compare FMFC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMFC
- NTHI
- Stock Information
- Founded
- FMFC 2016
- NTHI 2008
- Country
- FMFC Cambodia
- NTHI United States
- Employees
- FMFC N/A
- NTHI N/A
- Industry
- FMFC
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- FMFC
- NTHI Health Care
- Exchange
- FMFC NYSE
- NTHI Nasdaq
- Market Cap
- FMFC 116.5M
- NTHI 110.9M
- IPO Year
- FMFC 2025
- NTHI N/A
- Fundamental
- Price
- FMFC $7.22
- NTHI $4.75
- Analyst Decision
- FMFC
- NTHI
- Analyst Count
- FMFC 0
- NTHI 0
- Target Price
- FMFC N/A
- NTHI N/A
- AVG Volume (30 Days)
- FMFC 580.8K
- NTHI 540.0K
- Earning Date
- FMFC 01-01-0001
- NTHI 01-01-0001
- Dividend Yield
- FMFC N/A
- NTHI N/A
- EPS Growth
- FMFC N/A
- NTHI N/A
- EPS
- FMFC 0.01
- NTHI N/A
- Revenue
- FMFC $17,186,677.00
- NTHI $79,990.00
- Revenue This Year
- FMFC N/A
- NTHI N/A
- Revenue Next Year
- FMFC N/A
- NTHI N/A
- P/E Ratio
- FMFC $627.55
- NTHI N/A
- Revenue Growth
- FMFC 3.71
- NTHI 13.52
- 52 Week Low
- FMFC $4.20
- NTHI $3.20
- 52 Week High
- FMFC $7.59
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- FMFC N/A
- NTHI N/A
- Support Level
- FMFC N/A
- NTHI N/A
- Resistance Level
- FMFC N/A
- NTHI N/A
- Average True Range (ATR)
- FMFC 0.00
- NTHI 0.00
- MACD
- FMFC 0.00
- NTHI 0.00
- Stochastic Oscillator
- FMFC 0.00
- NTHI 0.00
About FMFC KANDAL M VENTURE LIMITED
Kandal M Venture Ltd is engaged in manufacturing affordable luxury leather goods. The company manufactures handbags, such as shoulder bags, crossbody bags, tote bags, backpacks, top-handle handbags, satchels, and other smaller leather goods, such as wallets. Geographically, the company derives maximum revenue from the United States.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").